[Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
In a three-week crossover controlled the authors administered alternately sulpiride and perphenazine with an intermittent placebo interval, to 40 hospitalized patients with acute exacerbation of schizophrenic and schizoaffective psychosis. According to evaluation recommended by Serejský significantly more complete remissions type AB were achieved especially in schizodepressive patients given sulpiride. The global score of BPRS and FKP scales after administration of the two tested neuroleptic drugs differed: sulpiride had a more favourable effect on depression, emotional withdrawal, reduced affectivity, slower motor activity, worry about the somatic state and hallucinations, while perphenazine gave better results in patients with reduced compliance, lack of cooperation, hostility and excitation. Sulpiride is well tolerated by the patients. Pharmacological parkinsonoid was observed only in cca half the patients, as compared with perphenazine and therefore also the need of correction by antiparkinsonian drugs was significantly smalled. The low incidence of extrapyramidal, hypnosedative and autonomous undesirable effects gave sulpiride the optimal position in our classification of 16 tested neuroleptic drugs. In one third of the patients no undesirable side--effects were observed.